Clinical Trial Update: Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pirfenidone vs placebo for fibrotic pulmonary sequelae after COVID-19 infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrotic Pulmonary Sequelae After COVID-19 Infection

Drugs mentioned

• PIRFENIDONE (pirfenidone)

Snippet

Sponsor: Institut d'Investigació Biomèdica de Bellvitge | Conditions: Fibrotic Pulmonary Sequelae Post-COVID19 Infection | Phase 2 | Status: UNKNOWN